Psychology Wiki

An opioid is any agent that binds to opioid receptors, found principally in the central nervous system and gastrointestinal tract. There are four broad classes of opioids: endogenous opioid peptides, produced in the body; opium alkaloids, such as morphine (the prototypical opioid) and codeine; semi-synthetic opioids such as heroin and oxycodone; and fully synthetic opioids such as pethidine and methadone that have structures unrelated to the opium alkaloids.

Although the term opiate is often used as a synonym for opioid, it is more properly limited to the natural opium alkaloids and the semi-synthetics derived from them.


Main article: opioid receptor

Opioids bind to specific opioid receptors in the central nervous system and in other tissues. There are at least four major classes of opioid receptors: μ, κ, δ and possibly σ. In addition, there are two subtypes of μ receptor: μ1 and μ2.These are all G-protein coupled receptors acting on GABAergic neurotransmission. The pharmacodynamic response to an opioid depends on which receptor it binds, its affinity for that receptor, and whether the opioid is an agonist or an antagonist. For example, the supraspinal analgesic properties of the opioid agonist morphine are mediated by activation of the μ1 receptor, respiratory depression and physical dependence (dependency) by the μ2 receptor, and sedation and spinal analgesia by the κ receptor.


Clinical use

Opioids have long been used to treat acute pain (such as post-operative pain). They have also found to be invaluable in palliative care to alleviate the severe, chronic, disabling pain of terminal conditions such as cancer. Very high doses are often required in palliation to improve the patients' terminal quality-of-life.

In recent years there has been an increased use of opioids in the management of non-malignant chronic pain. This trend is still somewhat controversial due to issues of dependence.

As recently as the early 20th century, opioids were administered by doctors to treat severe depression and other psychiatric disorders. The practice was discontinued because of the addictive potential of opioids. In recent decades, researchers have experimented with mixed opioid agonist/antagonists such as buprenorphine for the treatment of depression and other psychiatric disorders, encouraged by the decreased liability toward abuse of and dependence on these compounds, compared with full opioid agonists. [How to reference and link to summary or text]

United States

The sole clinical indications for opioids in the US, according to Drug Facts and Comparisons, 2005, are

Opioids are prohibited for psychological relief (with the narrow exception of anxiety due to shortness of breath), despite their extensively reported psychological benefits. The basis for this prohibition is not therapeutic but legal (fear of addiction and diversion). The prohibition allows no exceptions, even in areas where researchers have reported opioids to be especially effective and where the possibility of addiction or diversion is very low — for example, in the treatment of senile dementia, geriatric depression, and psychological distress due to chemotherapy or terminal diagnosis.

Recreational use and abuse

Most opioids produce euphoria in many people when ingested orally, intravenously, subcutaneously, rectally, through the nasal membranes, or when smoked. Recreational use and abuse of opioids usually is motivated by a desire to experience this euphoria, which can easily lead to addiction. Tolerance develops rapidly; a regular user may require significantly higher dosages of the drug to achieve the desired effect.


Non-clinical use and off-label clinical use were criminalized in the USA by the Harrison Narcotics Tax Act of 1914, and by other laws worldwide. Since then, nearly all non-clinical use and off-label clinical use of opioids has been rated zero on the scale of approval of nearly every social institution. However, in UK the 1926 report of the Departmental Committee on Morphine and Heroin Addiction under the Chairmanship of the President of the Royal College of Physicians reasserted medical control and established the "British system" of control — which lasted until the 1960s; in the US the Controlled Substances Act of 1970 markedly relaxed the harshness of the Harrison Act.

Before the twentieth century, institutional approval was often higher, even in Europe and America. In some cultures, approval of opioids was significantly higher than approval of alcohol.

Adverse effects

Opioids are associated with a range of adverse drug reactions - mostly associated with their pharmacological actions at opioid receptors.

Common adverse reactions include: nausea and vomiting, drowsiness, dizziness, headache, orthostatic hypotension, itch, dry mouth, miosis, urinary retention, and constipation. (Rossi, 2005)

Infrequent adverse reactions include: dose-related respiratory depression (see below), confusion, hallucinations, delirium, urticaria, hypothermia, bradycardia/tachycardia, ureteric or biliary spasm, muscle rigidity, myoclonus (with high doses), and flushing (due to histamine release, except fentanyl and remifentanil). (Rossi, 2005).

The most serious adverse reaction associated with opioid use is respiratory depression. This can occur with a single dose. Although tolerance develops rapidly, respiratory depression is the mechanism behind the fatal consequences of overdose.

Chronic use of opioids may result in serious constipation, which may progress to bowel obstruction, fecal impaction, or paralytic ileus. Because these conditions may require surgical intervention, stimulant laxatives are generally given as an adjunct to prevent these complications. Physiological tolerance does not develop with regard to constipation. It should be noted that in some therapeutic regimens (such as those aimed at treating diarrhea), mild constipation is a desired effect and hence laxatives would not be given.

With some individuals, opioid use can result in opioid-induced hyperalgesia, whereby individuals using opioids to relieve pain may paradoxically have more pain as a result of their medication. This phenomenon likely results from changes in NMDA receptors in the dorsal horn of the spinal cord.

Both therapeutic and chronic use of opioids can compromise the function of the immune system. Opioids decrease the proliferation of macrophage progenitor cells and lymphocytes, and affect cell differentiation. (Roy & Loh, 1996) Opioids may also inhibit leukocyte migration.


Main article: Opiod overdose

Overdose of an opioid can be fatal. The mechanism occurs through depression of the respiratory drive, resulting in hypoxia and eventually death. Opioid overdose can be rapidly reversed with an opioid antagonist such as naloxone or naltrexone. These competitive antagonists bind to the opioid receptors with higher affinity than agonists but do not activate the receptors. This displaces the agonist, attenuating and/or reversing the agonist effects. However, the elimination half-life of naloxone can be shorter than that of the opioid itself, so repeat dosing or continuous infusion may be required.

Tolerance, Dependence, Addiction, and Abuse

Tolerance is the tendency of the body to adapt to the presence of opioids; this adaptation makes it necessary to use ever-increasing doses of opioids in order to achieve the same effects. Tolerance is more pronounced for some effects than for others.

Dependence is the tendency of the body to manifest a characteristic and unpleasant withdrawal syndrome if regular doses of opioids are abruptly discontinued after tolerance has developed.

Addiction is a psychological attachment to certain effects of opioids (such as the euphoria that many people experience when the drugs are taken in sufficiently large doses) that drives the user to take the drug despite adverse and maladaptive consequences. Dependency and the unpleasantness of withdrawal can work to maintain addiction, although they do not cause it.

All persons receiving opioids for any reason will develop some degree of tolerance and dependence over time, although recent research suggests that these effects can be reduced by the concominant administration of opioid antagonists. [1][2]. Some people will also develop addiction.

Abuse is the misuse or overuse of opioids; the phenomena of tolerance and dependency, combined with the addictive potential presented by some effects of opioids (such as euphoria), make these drugs prime candidates for drug abuse.

Pyschiatric nomenclature in the DSM-IV defines dependence as addiction. As a result, a diagnosis of dependence does not imply that discontinuance of opioids will necessarily trigger a withdrawal syndrome. The nomenclature is being reconsidered for DSM-V.


Tolerance can be detected within 12-24 hours of the administration of morphine (Rang et al., 2003), and similarly for some other opioid agonists. Tolerance results in the necessity for increasing the dose over time to achieve the desired clinical effect.

Tolerance appears to develop first to the analgesic, sedative, emetic, euphoric and respiratory depressive effects of opioids. The miotic and constipating effects are more resistant to the development of tolerance. (Rang et al., 2003)

Dependence and withdrawal issues

Main article: Opioid dependence

Regular use of an opioid for any reason rapidly induces physical dependence, characterized by a highly unpleasant withdrawal syndrome when the drug is discontinued or rapidly reduced in dosage, or when an antagonist is administered, although recent development promises the possibility of chronic opioid use without tolerance or withdrawal[1][2]. The acute withdrawal syndrome generally consists of signs and symptoms opposite to those of the drug when initially administered: severe dysphoria, anxiety, eye tearing, a runny nose, goose bumps, sweating, nausea, vomiting, cramps and deep pains are common. The speed and severity of withdrawal depends on the half-life of the opioid—heroin withdrawal occurs more quickly and is more severe than methadone withdrawal, but methadone withdrawal takes longer. The acute withdrawal phase is often followed by a protracted phase of depression and insomnia that can last for months.

Physical dependence is distinct from and does not imply psychological addiction, defined as uncontrolled drug use despite harm. However, physical dependence can aggravate psychological addiction when it occurs.

Some patients with narcotic dependence experience recurrent episodes of severe abdominal pain and nausea leading to hospitalizations and extensive diagnostic workups over periods of months to years. The intractable nausea resolves when the pain is treated with narcotics, the patient is able to go home, but another episode recurs when the pain medication runs out.

Withdrawal symptoms can be minimised by slowly tapering the dose over days or weeks, sometimes after switching to a long-acting opioid such as methadone. The symptoms of opioid withdrawal can also be treated with other medications, such as clonidine for sympathetic hyperactivity and a benzodiazepine for anxiety and insomnia.

"Rapid detox" is a relatively new technique that uses opioid antagonists to cause acute withdrawal while the patient is under general anesthesia to eliminate the otherwise extreme discomfort. This procedure has attracted controversy due to its high cost and risk; several patients have died during the procedure. Many pain specialists think that the procedure is unnecessary, and addiction specialists criticize it for doing nothing to keep an addict from relapsing into opioid abuse after the procedure is complete. Indeed, there have been reports of addicts undergoing rapid detox with the full intention of resuming addiction as the technique drastically reduces tolerance thus reducing the cost of addiction. Rapid detox also does not alleviate the protracted withdrawal syndrome that lasts for weeks or months after the acute phase.

Examples of opioids

Endogenous opioids

Opioid-peptides that are produced in the body:

Dynorphin Acts through κ-opioid receptors, and is widely distributed in the CNS, including in the spinal cord and hypothalamus, including in particular the arcuate nucleus and in both oxytocin and vasopressin neurons in the supraoptic nucleus.

[met]-enkephalin is widely distributed in the CNS;[met]-enkephalin is a product of the proenkephalin gene, and acts through μ and δ-opioid receptors.

[leu]-enkephalin , also a product of the proenkephalin gene, acts through δ-opioid receptors

Nociceptin, formerly known as orphanin FQ, is an opioid-related peptide, but it does not act at the classic opioid receptors and actions are not antagonised by the opioid antagonist naloxone. Nociceptin is a potent anti-analgesic. Noiceptin is widely distributed in the CNS; it is found in many regions of the hypothalamus, brainstem, forebrain, as well as in the ventral and dorsal horns of the spinal cord. Nociceptin acts at the NOP1 receptor, formerly known as ORL-1. The receptor is also widely distributed in the brain, including in the cortex, anterior olfactory nucleus, lateral septum, hypothalamus, hippocampus, amygdala, central gray, pontine nuclei, interpeduncular nucleus, substantia nigra, raphe complex, locus coeruleus, and spinal cord.

Endomorphin. Acts through μ-opioid receptors, and is more potent than other endogenous opioids at these receptors.

β-endorphin is expressed in POMC cells in the arcuate nucleus and in a small population of neurons in the brainstem, and acts through μ-opioid receptors. β-endorphin has many effects, including on sexual behavior and appetite.β-endorphin is also secreted into the circulation from pituitary corticotropes and melanotropes. α-neoendorphin is also expressed in POMC cells in the arcuate nucleus

Opium alkaloids

Phenanthrenes naturally occurring in opium:

Preparations of mixed opium alkaloids, including papaveretum, are still occasionally used.

Semisynthetic derivatives

Synthetic opioids




  • Pethidine (meperidine)
  • Ketobemidone
  • MPPP
  • Allylprodine
  • Prodine

Diphenylpropylamine derivatives

Benzomorphan derivatives

Oripavine derivatives

Morphinan derivatives


Opioid antagonists

See also

External links


  • Abse, D. Wilfred, William J. Rheuban, and Salman Akhtar, “The Poppy: Therapeutic Potential in Cases of Dementia with Depression”, in Opioids in Mental Illness: Theories, Clinical Observations, and Treatment Possibilities, edited by Karl Verebey, The New York Academy of Sciences, New York, New York, 1982, pp. 79ff.
  • Alexander, BK (2001): 'The Myth of Drug-Induced Addiction ' - Paper delivered to tthe Canadian Senate. Retrieved 01/Sep/2006.
  • Berridge, Virginia, Opium and the People: Opiate Use in Nineteenth-Century England, 1987.
  • Bodkin JA, Zornberg GL, Lukas SE, Cole JO (McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School), “Buprenorphine Treatment of Refractory Depression”, Journal of Clinical Psychopharmacology, February, 1995, 15(1):49-57,
  • Callaway, Enoch, Editorial [re buprenorphine for psychiatric problems], Biological Psychiatry, June 15, 1996.
  • Emrich, H. M., P. Vogt, and A. Herz (Max-Planck Institute for Psychiatry, Munich, Germany), "Possible Antidepressive Effects of Opioids: Action of Buprenorphine", in Opioids in Mental Illness: Theories, Clinical Observations, and Treatment Possibilities, edited by Karl Verebey, The New York Academy of Sciences, New York, New York, 1982, p. 108.
  • Gutstein, Howard B. and Huda Akil, “Opioid Analgesics”, in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition, 2006, edited by Brunton, Laurence L., John S. Lazo, Keith L. Parker, Iain L. O. Buxton, and Donald Blumenthal.
  • Mongan, Lou and Enoch Callaway, Letter to the Editor [re buprenorphine for psychiatric problems], Biological Psychiatry, 1990, Volume 28, Issue 12, pp. 1078ff.
  • Morgan GE, Mikhail MS, Murray MJ (2002). Clinical Anesthesiology (4 ed.). New York: McGraw-Hill. ISBN 0-07-142358-3.
  • Rang HP, Dale MM, Ritter JM, Moore PK (2003). Pharmacology (5 ed.). Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4.
  • Reynolds, A. K. and Lowell O. Randall, Morphine and Allied Drugs, 1959.
  • Rossi S (Ed.) (2004). Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2.
  • Rossi S (Ed.) (2005). Australian Medicines Handbook 2005. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-9-3.
  • Roy S, Loh HH (1996). Effects of opioids on the immune system. Neurochem Res 21 (11), 1375-86. PMID 8947928.
  • Verebey, Karl, editor, Opioids in Mental Illness: Theories, Clinical Observations, and Treatment Possibilities, The New York Academy of Sciences, New York, New York, 1982.

cs:Opioid da:Opioid de:Opioid es:Opioide fr:Opioïde hr:Opioidi lt:Opiatas hu:Opioid ms:Opioid no:Opioider pt:Opióide fi:Opioidi sv:Opioid th:โอปิออยด์

This page uses Creative Commons Licensed content from Wikipedia (view authors).